Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 715

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 715
---
ophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with or without neurodegenerative diseases EP 21305942.1                                                    |     | Europe        |     | Not Applicable               |     |                                                                                    |     | Compound for use |
| Benedin, Piperidine, 2-benzhydryl-3-hydroxy-N-methyl-, hydrochloride and derivatives thereof for treating neurological diseases associated with sleep disorders, Central Disorders of Hypersomnolence preferably Kleine-Levin Syndrome EP 21305946.2 |     | Europe        |     | Not Applicable               |     |                                                                                    |     | Compound for use |
| Lauflumide and derivatives thereof for treating chronic fatigue syndrome and                                                                                                                                                                         
 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) EP 21305944.7                                                                                                                                                                            |     | Europe        |     | Not Applicable               |     |                                                                                    |     | Compound for use |

Annex F-69

In addition to our patents and patent applications, we also rely on unpatented trade secrets, know -how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect our ownership of know -howand trade secrets through an active program of legal mechanism including invention assignments, confidentiality agreements, material transfer agreements, research collaborations and licenses to protect our product candidates. For a more comprehensive discussion of the risks related to our intellectual property, please see Item 3.D. “Risk Factors — Risks Related to Our Intellectual Property.” Competition The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions, which may in the future develop products to treat those diseases that we currently or, in the future, seek to treat. Any product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. Many of our competitors have far greater marketing and research capabilities than us. All of these companies and institutions may have product candidates in development that are or may become superior to Quilience and Nolazol. Our commercial opportunity would be reduced significantly if our competitors develop and commercialize products that are safer, more effective, more convenient, have fewer side effects or are less expensive